glp-1 obesity drug news today 2025-10-20 GLP-1s: The Swiss Army Knife Tackling More Than The Obesity-Drug Revolution Is Stalling

DHAR1 has dual functions: soluble protein, it demonstrates GSH-dependent thiol transferase and dehydroascorbate (DHA) reductase activities, and is involved in redox homeostasis

Weeks 1 to 2: Sleep depth

6c and d)

Methods Study design Representatives of the companies Bristol-Myers Squibb, Novo Nordisk, Sanofi, Merck, Novartis, Boehringer Ingelheim and Takeda were contacted with the request to provide the event numbers of acute pancreatitis with the respective drug and non-incretin comparators as well as the corresponding number of patient-years of exposure (PYOs) for the approved GLP-1 receptor agonists exenatide twice daily, exenatide weekly, liraglutide and lixisenatide, as well as the DPP-4 inhibitors sitagliptin, saxagliptin, vildagliptin, alogliptin and linagliptin